vTv Therapeutics Inc
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its product pipeline includes TTP399, TTP273, HPP737 and HPP593. The lead product candidate, cadisegliatin (TTP399), is an orally administered, small-molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). HPP737 is an orally administered, non-central nervous system (non-CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and offers the potential for an improved tolerability profile and efficacy over commercially available PDE4 inhibitors. TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus. Its product pipeline also includes Azeliragon and HPP3033.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying vTv Therapeutics stock, anticipating its price could rise significantly.
Financial Health
vTv Therapeutics Inc has modest revenue and cash flow, but its financial position needs improvement.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring VTVT
GLP-1s Target Liver Disease
The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.
Published: August 19, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical-stage catalysts
Trial readouts and regulatory milestones can create sharp share-price moves, though outcomes are uncertain and may disappoint.
Pipeline and focus
The company focuses on small-molecule therapies in metabolic and neurological areas, offering potential upside alongside typical clinical-stage risk.
Capital and partners
Watch cash runway and any licensing or partnership activity, since raising funds could dilute holders while deals can de‑risk programmes.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
